Company / Return on Equity (ROE)
Edgewise Therapeutics, Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-32.1%
FY2025
5-year range
-32.1% / -15.6%
FY2021-FY2025
Trend
-10.3%
vs FY2024
Sector context
#103 of 190
Health Care
What the data says
Edgewise Therapeutics, Inc. reports negative total equity of -32.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-32.1% in FY2025 with a 3-year CAGR of -12.6%.
Declined from -31.4% to -32.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -12.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#103 of 190 in Health CareTop 54% of 190This company -32.1% Sector average -50.4%
▼
+36.3% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 10.3% year-over-year.
- Currently 18.3pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -32.1% | -10.3% |
| FY2024 | -29.1% | +7.3% |
| FY2023 | -31.4% | -61.0% |
| FY2022 | -19.5% | -25.1% |
| FY2021 | -15.6% | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026